Back to top
more

Chugai Pharmaceutical Co. (CHGCY)

(Delayed Data from OTC)

$18.95 USD

18.95
111,478

+0.36 (1.94%)

Updated Jul 22, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?

Here is how Brookdale Senior Living (BKD) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

Here is how Boston Scientific (BSX) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's What You Should Know

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) delivered earnings and revenue surprises of -17.65% and 3.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -41.94% and 28.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q1 Loss, Misses Revenue Estimates

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -9.52% and 10.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Select Medical (SEM) Q1 Earnings and Revenues Surpass Estimates

Select Medical (SEM) delivered earnings and revenue surprises of 51.35% and 3.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Shaun Pruitt headshot

3 Stocks to Consider with Earnings Approaching

As we progress through earnings season several top-rated Zacks stocks are expected to report their first quarter results on Monday, April 24.

TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -34.86% and 1.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 10.64% and 4.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Has Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Outpaced Other Medical Stocks This Year?

Here is how Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.